Scroll To Top
Search by Speciality

1st Annual European Congress on Breast Cancer

The Westin Paris-Vendôme | Paris, FRANCE
From 149 to 349 EUR
Event Preview
This event
is Finished
Title: 1st Annual European Congress on Breast Cancer
Specialty: Cardiology
Dates: From Oct, 13, 2017 to Oct, 14, 2017
Location: Paris, FRANCE
Type: Congress
Registration Cost: From 149 to 349 EUR
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Paris, France.
General Info
Event Venue:

The Westin Paris-Vendôme

Paris, FRANCE Visit the Venue to read more
Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:

New agents, emerging strategies, and optimization of established regimens are changing the delivery of breast cancer therapy. Over the past decade, tremendous progress in the treatment of breast cancers has led to improved outcomes for patients, but has also complicated clinical management in this setting. We are excited to announce the 1st Annual European Congress on Breast Cancer™, a comprehensive educational conference designed to help practitioners place emerging information into the context of landmark clinical trial data and established standards of care, with the goal of ultimately improving the care they provide to their patients with breast cancers.

This practical and interactive multiday program features a faculty of leading international experts who will provide up-to-date information and guidance via didactic lectures, question-and-answer sessions, and extended interactive, case-based panel discussions. This format will enable participants to engage the faculty in a direct exchange of perspectives, personal experiences, and strategies related to clinical challenges in the management of breast cancers.

This meeting is not to be missed! The activity will to continue the legacy and tradition of Physicians’ Education Resource®, LLC, in providing clinicians with the knowledge and confidence to maintain state-of-the-art care and to optimize outcomes for patients with cancer.

Can't Miss Topics

Perspectives on emerging strategies

Immunotherapeutics for early-stage, triple-negative breast cancer (TNBC)

Antibody-drug conjugates in metastatic TNBC

Molecular testing for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer

Targeted therapies for HER2-positive metastatic breast cancer

Robot-assisted surgery

Short preoperative systemic therapy for early luminal breast cancer

Genomics for hormone-receptor (HR)‒positive, metastatic breast cancer

Patient selection for carboplatin in early TNBC

How to treat residual TNBC after neoadjuvant chemotherapy

Germline alteration testing in TNBC

Clinical updates on targeted therapies including T-DM1, PI3K inhibitors, PARP inhibitors, CDK4/6 inhibition, and HER2-targeted agents

Management of brain metastases

Treatment de-escalation for small HER2-positive tumors

Updates in locoregional therapies

Practical guidance on individualizing and optimizing therapy, including endocrine and anthracycline-free regimens

Challenging case debates

And more!

Target Audience

This educational activity is directed toward health care professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other health care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc) involved in the treatment and management of patients with breast cancer.

Educational Objectives

At the conclusion of this activity, participants should be better prepared to:

Incorporate current guidelines and recent data on local and locoregional therapies into the treatment of patients with breast cancer

Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision making for breast cancer appropriately

Review current standards and emerging data regarding systemic therapies for the treatment of early-stage, locally advanced, and metastatic breast cancer

Consider therapeutic effectiveness, as well as patient and tumor characteristics, in individualizing treatment plans for patients receiving systemic therapies for breast cancer

Identify appropriate clinical trials designed to benefit patients with breast cancer


Giuseppe Curigliano, MD, PhD

Chair, Division of Early Drug Development

European Institute of Oncology

Milan, Italy



Sibylle Loibl, MD, PhD

Co-Chair for the German Breast Group (GBG)

Associate Professor

University of Frankfurt

Frankfurt, Germany


David Miles, MBBS, BSc, MD, FRCP

Profesor and Lead Clinician Breast Cancer

Mount Vernon Cancer Centre

Middlesex, United Kingdom



Roberto Orecchia, MD, PhD

Professor of Radiation Therapy

Director of School of Radiation Therapy and

School of Health Techniques of Medical Radiology

University of Milan

Milan, Italy

Registration Needs updating Register Now


Registration Cost
Early Registration

Late Registration From: 2017-09-06 To: 0--
On site Registration

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts


The Westin Paris-Vendôme

3 Rue de Castiglione

Paris, 75001, France

Tel: +33 (0) 1 44 77 11 11

Scientific Content Up to Date
Submission Info
Sponsors Exhibitors
General Info

Contact No.: (609) 378-3701


Organising Agency

Contact No.: (609) 378-3701


Event map
Revelant Events